Health 26 May 2026 - 2 June 2026

DiaMedica Shares Down Ahead of Stroke Trial Update
····

DiaMedica Shares Down Ahead of Stroke Trial Update

DiaMedica Therapeutics Inc. shares fell Tuesday, with the drug developer closing lower as the major indexes gained. The stock was last at $5.77 after hours, off 6 cents from its close. It traded between $6.29 and $5.56 earlier in the session. Volume reached about 152,000 shares. Market cap was roughly $311 million. DiaMedica is heading into a catalyst week as it prepares to present at 3:45 p.m. ET Thursday during the Jefferies Global Healthcare Conference in New York. The event, which runs June 2-4, draws attention from healthcare investors looking for pipeline news and signs of financing.
June 2, 2026
Aura Biosciences Stock Falls After Eye-Cancer Trial News
····

Aura Biosciences Stock Falls After Eye-Cancer Trial News

Aura Biosciences shares dropped roughly 4.2% to $6.89 late Tuesday, lagging a soft biotech sector. This came after Aura said on Monday that it hit a clinical-trial milestone. The SPDR S&P Biotech ETF slid about 4.2%. The iShares Nasdaq Biotechnology ETF lost around 2.9%. Aura said Monday it finished enrolling 108 patients in CoMpass, its Phase 3 study of bel-sar for early choroidal melanoma. Phase 3 trials are key late-stage tests before a drug approval. The first main results, or “topline” data, are due in the second half of 2027.
June 2, 2026
Neuronetics Stock Drops As Traders Watch New TMS Research Effort
·····

Neuronetics Stock Drops As Traders Watch New TMS Research Effort

Neuronetics Inc. dropped 5.7% to $1.575 Tuesday. This comes after the company announced that new NeuroStar data will be presented this week at a big transcranial magnetic stimulation conference. NEUR opened at $1.67, hit $1.76 before slipping to around $1.57, with volume near 785,000 shares. Timing is key here. Neuronetics wants to prove its NeuroStar system has stronger evidence behind it, even as the company deals with a balance-sheet crunch. Transcranial magnetic stimulation, or TMS, is a non-invasive therapy that uses magnetic pulses on specific brain regions, usually for patients whose depression hasn’t responded to medication.
June 2, 2026
Cardio Diagnostics Stock Jumps as Tiny Heart-Test Firm Heads Into June Benefits Push
····

Cardio Diagnostics Stock Jumps as Tiny Heart-Test Firm Heads Into June Benefits Push

Cardio Diagnostics Holdings Inc shares rose again on Tuesday, extending the prior session’s jump, as traders focused on the micro-cap cardiovascular diagnostics firm’s push into employer health-benefit channels rather than a fresh earnings report. Micro-cap means a company with a very small stock-market value. The stock was recently at $2.27, up 6.6%, giving the Chicago-based company a market value of about $6.45 million. Shares closed Monday at $2.13, up 12.7%, on volume of 95,943 shares.
June 2, 2026
Capricor Shares Fall, FDA Call in August Looms
····

Capricor Shares Fall, FDA Call in August Looms

Capricor Therapeutics shares moved lower in early trading Tuesday, following a 4.8% decline in the regular session. The rare-disease biotech is trading near $28.53 before the bell, as the stock stays focused on its looming U.S. regulatory date, not the broader market rally. Capricor’s current market value stands at around $1.64 billion. Capricor isn’t trading like a typical small-cap biotech anymore. Its valuation is tied to deramiocel, its experimental cell therapy for Duchenne muscular dystrophy, and the decision from the U.S. Food and Drug Administration, due by Aug. 22.
June 2, 2026
Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial
····

Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial

Journey Medical Corp was down 3.5% at $6.09 late Monday, putting the company's market cap around $166 million. The Scottsdale-based maker of dermatology drugs trailed the SPDR S&P Biotech ETF, which slipped 2.2%. No new company statement has landed in the past two days. Journey’s investor page still shows the last update as May 19, when it flagged its slot at A.G.P.’s Annual Virtual Healthcare Conference. Before that, the site posted Journey’s May 13 Q1 earnings.
June 2, 2026
Alnylam Near 52-Week Low With Amvuttra in Focus
····

Alnylam Near 52-Week Low With Amvuttra in Focus

Alnylam Pharmaceuticals dropped 2.16% to finish Monday at $295.47, and was just above that level in after-hours action. The Cambridge, Massachusetts biotech is sitting about 4% above its 52-week low, down about 40% from an October high. Shares moved in a $295.14 to $303.98 range for the day. The market lost ground on that news. U.S. stocks were mostly higher, with Reuters saying the S&P 500 was up 0.43% and the Nasdaq up 0.69% as tech names gained. Only technology and energy were in the green out of the 11 S&P sectors. Alnylam’s story is different, though—a heart-drug stock that’s still stuck at the low end of its one-year range.
June 1, 2026
Opus Genetics Slides Ahead of June Test
····

Opus Genetics Slides Ahead of June Test

Opus Genetics Inc. shares eased late Monday morning, retracing some of Friday’s advance. Investors are watching for the gene-therapy company’s slot at the Jefferies Global Healthcare Conference this week. The stock, which trades on the Nasdaq, slipped 7 cents to $4.29, off 1.6%. Shares opened at $4.40 and ranged from $4.20 to $4.49. Volume was roughly 288,500 shares. Market cap sat near $373 million.
June 1, 2026
Cybin Shares Up Slightly as HELP Backers Focus on Main Trial
····

Cybin Shares Up Slightly as HELP Backers Focus on Main Trial

Cybin Inc., which trades as Helus Pharma, ticked up Friday. HELP shares on Nasdaq were last seen at $4.55, up 6 cents, or 1.3%. The stock moved between $4.42 and $4.58. Around 385,000 shares traded. Helus Pharma shares barely budged in light trading. With nothing new since the April 30 update on the investor page, the stock traded off sector interest and speculation around the company’s next move instead of reacting to a Friday headline.
May 30, 2026
Celcuity Rises Ahead of ASCO Update With FDA Deadline Pressing
····

Celcuity Rises Ahead of ASCO Update With FDA Deadline Pressing

Celcuity Inc. shares gained late Friday, topping the biotech sector as the company heads toward several cancer-drug updates, investor meetings, and an upcoming FDA decision date. Shares of the Minneapolis-based biotech traded at $132.88, adding $2.14, or around 1.6% on the day. The SPDR S&P Biotech ETF edged up roughly 0.5%. The iShares Nasdaq Biotechnology ETF was little changed.
May 30, 2026
vTv Therapeutics Drops as Diabetes Study Date Approaches
····

vTv Therapeutics Drops as Diabetes Study Date Approaches

vTv Therapeutics Inc. shares fell 1.1% to $33.14 Friday afternoon, lagging behind a stronger biotech market with investors waiting on further news from its diabetes program. The SPDR S&P Biotech ETF gained around 0.8%, and the iShares Nasdaq Biotechnology ETF was up 0.2%. vTv shares are trading now mostly on prospects for cadisegliatin, its oral candidate being trialed as an add-on to insulin in type 1 diabetes. The company said in a May 13 update that it still expects to finish enrolling its Phase 3 CATT1 study in the third quarter of 2026.
May 29, 2026
Apyx Medical Shares Rise 6% as Body-Contouring Push Hits New Milestone
····

Apyx Medical Shares Rise 6% as Body-Contouring Push Hits New Milestone

Apyx Medical Corporation jumped 6.4% in late trading Thursday, up 25 cents to $4.15. The move brought some focus back to its Renuvion and AYON body-contouring products. Shares changed hands between $3.87 and $4.21. The market cap was near $174 million at the last price. Apyx said Wednesday its latest update wasn’t an earnings release. The company announced “Body by Apyx” will return to Miami Swim Week, bringing Renuvion patients and featuring the AYON system. AYON combines Renuvion, liposuction, infiltration, aspiration and electrocautery on one platform. “The market continues to evolve,” said Regis Cain, senior director of marketing at Apyx, as patients look for more complete body-contouring.
May 28, 2026
BeOne Dips on Wall Street After Cancer Results, Market Looks On
·······

BeOne Dips on Wall Street After Cancer Results, Market Looks On

BeOne Medicines AG shares lost ground Thursday afternoon even as the biotech sector moved higher. Investors took in fresh late-stage cancer data, but enthusiasm around the company’s oncology pipeline already looked priced in. ONC slipped 2.7% to $291.98 at 2:57 p.m. EDT. The Nasdaq Biotechnology Index was up 1.1%. The gap stood out after BeOne shared a new update that came in positive on the science. Still, traders didn’t show much appetite for ONC ahead of more ASCO data due next week.
May 28, 2026
Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing
····

Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing

Viking Therapeutics Inc. shares picked up 1.7% to $32.19 on Thursday afternoon. Lake Street rolled out new coverage with a bullish call on the obesity-drug company. The stock moved in a range of $31.39 to $32.22. Market cap was around $3.72 billion. Viking remains a clinical-stage drugmaker, with most of its worth tied to treatments in development rather than products on the market. Investors are looking at its obesity drug VK2735, now heading for Phase 3 trials, to see if it can make it through the final testing needed for approval as obesity treatments keep moving toward oral and injectable options.
May 28, 2026
Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test
····

Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test

Moderna shares slipped at the open on the Nasdaq Thursday. Investors watched as a U.S. Food and Drug Administration advisory committee met to discuss what might be next for COVID-19 vaccines. The stock dropped around 2.6% to $46.39, trailing both the iShares Nasdaq Biotechnology ETF, which was steady, and the SPDR S&P Biotech ETF, off about 0.6%. Pfizer was close to flat. BioNTech slid roughly 1.3%.
May 28, 2026
····

Xerox pops after 15 million-share filing seen as turnaround signal

Xerox Holdings shares traded higher Thursday after a new SEC filing disclosed the updated share count, as the office-technology company works on its turnaround plan. Xerox inched up 8 cents to $3.18 on Nasdaq. Volume was about 1.6 million shares, giving the company a market value of $416 million. The stock moved between $3.05 and $3.23 during the session. The Nasdaq Composite and S&P 500 both closed flat.
May 28, 2026
CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test
····

CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test

CapsoVision Inc. shares edged higher in late Wednesday morning trading, outpacing a weaker medical-device sector as investors stayed focused on the company’s pending artificial-intelligence product work rather than its still-thin revenue base. The stock was up 5 cents, or about 0.8%, at $6.67 in the latest available trade at 10:45 a.m. EDT, with volume of 14,335 shares. The iShares U.S. Medical Devices ETF fell about 1.4%, while the SPDR S&P 500 ETF was little changed.
May 27, 2026
Check-Cap Shares Move as MBody AI Merger Heads Toward Nasdaq Wrap
····

Check-Cap Shares Move as MBody AI Merger Heads Toward Nasdaq Wrap

Check-Cap Ltd. shares are in focus before the U.S. open Wednesday, after the company said its merger partner MBody AI plans to show its enterprise robotics platform to institutional investors in Miami this week. Check-Cap isn’t just a medical-diagnostics name anymore. The small Nasdaq-listed stock is trying to remake itself as a bet on embodied artificial intelligence, or software for robots and machines to act out in the real world, via its planned merger with MBody AI.
May 27, 2026
Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race
····

Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race

Arrowhead Pharmaceuticals stock climbed about 5% to $78.68 late Tuesday. The rise brought the company’s market cap to roughly $11.2 billion. Arrowhead released new plozasiran data at the European Atherosclerosis Society meeting in Athens. The company said results back using a 25-mg dose, without need for adjustment, in patients with moderate-to-severe kidney issues or moderate liver impairment. “This is an important step,” said Jennifer Hellawell, vice president of clinical development. The readout has new weight because plozasiran got its first FDA nod back in November. Redemplo cleared the agency for familial chylomicronemia syndrome, or FCS, a genetic disease that keeps people from breaking down triglycerides, the fat in blood. The FDA says a normal level is under 150 mg/dL—over 500
May 27, 2026
United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone
····

United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone

United Therapeutics shares gained 1.4% to $576.30 in early-afternoon trade Tuesday. The stock opened at $564.61 and reached as high as $576.99 intraday. Market cap was about $27.2 billion. Nasdaq opened again after the Memorial Day break, pushing broader stock indexes higher in early U.S. trading. Tech stocks took the lead, with the Nasdaq out in front. Growth-focused healthcare shares also got a lift compared to trading before the holiday.
May 26, 2026
1 2 3 … 6